ClinicalTrials.gg
CompletedNCT05564299Updated Sep 23, 2025Results posted

Rapid Diagnostic Assay for Gonorrhea and Chlamydia

An interventional study of Rapid 30-minute Desktop Assay in Urethritis, Cervicitis and Sexually Transmitted Infections, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.

Enrollment
207th of 251
98 · median 400
Started
2023
with 13 others
No phase
190 of 283
24 open now
Registered
231st of 283
by date

Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 207th largest by enrollment of the 251 interventional ones that give a count, is one of 14 that started in 2023, is one of 190 with no phase, and was the 231st registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Sexually Transmitted Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is a pilot randomized controlled trial evaluating the use of either a) rapid 30-minute desktop assay or b) point-of-care gram stain (current standard of care) to guide the clinical management of patients with symptomatic urethritis or cervicitis evaluated in the Massachusetts General Hospital Sexual Health Clinic. Patients presenting with symptoms of urethritis or cervicitis and meeting inclusion criteria will be randomized to have diagnostic specimens tested during the clinical encounter using either the 30-minute desktop assay or point-of-care gram stain. Patients randomized to the intervention arm of the study will also have a gram stain created, which will be held for interpretation by the clinician following the clinical encounter. Patients will not be followed longitudinally. Recruitment will conclude when 100 participants enroll in the study.

03

Conditions studied

  • Urethritis
  • Cervicitis
  • Sexually Transmitted Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age and older
  • Presenting with symptoms of acute urethritis or cervicitis
  • Willing to provide urine or additional vaginal swab specimen

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
  • Presenting with symptoms not consistent with urethritis or cervicitis
  • Unwilling or unable to provide urine or vaginal swab specimen
  • Pregnant
  • Contact of index patients with Gonorrhea or Chlamydia
  • Known exposure to Gonorrhea or Chlamydia
  • Reporting concurrent symptoms at a non-genital site
  • Suspected or confirmed to have Monkeypox
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • No intervention
    Standard of Care

    Point-of-care gram stain

  • Experimental
    Rapid STI Test

    Diagnostic Test: Rapid 30-minute Desktop Assay

Interventions

  • Diagnostic testRapid 30-minute Desktop Assay

    Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter. Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay. Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols.

06

What researchers measure

Primary outcomes

  1. Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis

    The investigators will compare the mean antibiotic days of therapy (DOT) administered per patient at the time of initial ciinical visit when evaluated with either point-of-care gram stain or rapid 30-minute desktop test.

    Time frame: Day 1

Secondary outcomes

  1. Participant Visit Duration

    The investigators will compare visit duration between participants randomized to the point-of-care test and those to the 30-minute desktop test. Participant visit duration will be calculated as the difference between when the participant enters the exam room and when they check out of the clinic, in minutes.

    Time frame: Day 1

  2. Sample Processing Time

    The investigators will compare the time taken to process clinical specimen using either the point-of-care gram stain or rapid 30-minute desktop test. The provider processing the samples will record the start and end times on a time sheet, and the sample processing time will be calculated as the difference between those entries, in minutes.

    Time frame: Day 1

  3. Time to Result

    The investigators will compare time from specimen collection to availability of test result between the point-of-care gram stain or rapid 30-minute desktop test. Providers will record time of specimen collection and time of result (for point of care gram stain), time of result for the rapid desktop platform will be extracted from the platform; time to result will be calculated as the difference between those times, in minutes.

    Time frame: Day 1

  4. Test-concordant Antibiotic Use for Gonorrhea

    Proportion of participants in each arm who recevied gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was positive for gonorrhea, or who did not receive gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was negative for gonorrhea

    Time frame: Day 1

  5. Diagnosis-concordant Antibiotic Use for Gonorrhea

    Proportion of participants in each arm who were prescribed an antibiotic with activity against gonorrhea on the day of clinic visit, either for a positive test result or for a clinical syndrome for which the antibiotics are indicated (e.g., a clinical diagnosis of pelvic inflammatory disease, a diagnosis of non-gonococcal urethritis) as determined by study PI; or who were not prescribed an antibiotic with activity against gonorrhea on the day of clinic visit in the absence of a positive test result for gonorrhea or clinical syndrome for which the antibiotics are indicated.

    Time frame: Day 1

  6. Proportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results

    The proportion of point of care gram stain results (control arm) or rapid test results (intervention arm) that were unavailable or invalid (unable to be read or provided an error message) at the time of the clinic visit.

    Time frame: Day 1

Other outcomes

  1. Clinic Provider Perspectives on Rapid STI Testing

    Clinic provider perspectives will be elicited during a focus group discussion at the conclusion of the clinical study.

    Time frame: at study completion: 12 months

07

Results

Posted Sep 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneStandard of CareRapid STI Test
Started4949
Completed4949
Not completed00

Outcome measures

PrimaryMean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis

The investigators will compare the mean antibiotic days of therapy (DOT) administered per patient at the time of initial ciinical visit when evaluated with either point-of-care gram stain or rapid 30-minute desktop test.

Time frame:
Day 1
Reported as:
Median · Antibiotic days of therapy (DOT)
Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis
Antibiotic days of therapy (DOT)Standard of CareRapid STI Test
Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis7 (0 to 8)1 (0 to 7)
Statistical analysis
  • Standard of Care vs Rapid STI Test · Wilcoxon (Mann-Whitney) · p = 0.053
SecondaryParticipant Visit Duration

The investigators will compare visit duration between participants randomized to the point-of-care test and those to the 30-minute desktop test. Participant visit duration will be calculated as the difference between when the participant enters the exam room and when they check out of the clinic, in minutes.

Time frame:
Day 1
Reported as:
Median · Minutes
Participant Visit Duration
MinutesStandard of CareRapid STI Test
Participant Visit Duration57 (45 to 69)87 (72 to 97)
SecondarySample Processing Time

The investigators will compare the time taken to process clinical specimen using either the point-of-care gram stain or rapid 30-minute desktop test. The provider processing the samples will record the start and end times on a time sheet, and the sample processing time will be calculated as the difference between those entries, in minutes.

Time frame:
Day 1

No measurements were reported for this outcome.

SecondaryTime to Result

The investigators will compare time from specimen collection to availability of test result between the point-of-care gram stain or rapid 30-minute desktop test. Providers will record time of specimen collection and time of result (for point of care gram stain), time of result for the rapid desktop platform will be extracted from the platform; time to result will be calculated as the difference between those times, in minutes.

Time frame:
Day 1
Reported as:
Median · Minutes
Time to Result
MinutesStandard of CareRapid STI Test
Time to Result6.5 (5 to 9)34 (33 to 36)
SecondaryTest-concordant Antibiotic Use for Gonorrhea

Proportion of participants in each arm who recevied gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was positive for gonorrhea, or who did not receive gonorrhea-active antibiotics if PCR-based testing (rapid test or MDPH) was negative for gonorrhea

Time frame:
Day 1
Reported as:
Count of participants · Participants
Test-concordant Antibiotic Use for Gonorrhea
ParticipantsStandard of CareRapid STI Test
Test-concordant Antibiotic Use for Gonorrhea4146
SecondaryDiagnosis-concordant Antibiotic Use for Gonorrhea

Proportion of participants in each arm who were prescribed an antibiotic with activity against gonorrhea on the day of clinic visit, either for a positive test result or for a clinical syndrome for which the antibiotics are indicated (e.g., a clinical diagnosis of pelvic inflammatory disease, a diagnosis of non-gonococcal urethritis) as determined by study PI; or who were not prescribed an antibiotic with activity against gonorrhea on the day of clinic visit in the absence of a positive test result for gonorrhea or clinical syndrome for which the antibiotics are indicated.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Diagnosis-concordant Antibiotic Use for Gonorrhea
ParticipantsStandard of CareRapid STI Test
Diagnosis-concordant Antibiotic Use for Gonorrhea4348
SecondaryProportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results

The proportion of point of care gram stain results (control arm) or rapid test results (intervention arm) that were unavailable or invalid (unable to be read or provided an error message) at the time of the clinic visit.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Proportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results
ParticipantsStandard of CareRapid STI Test
Proportion of Participants With Invalid or Unavailable Point of Care Gram Stain or Rapid STI Test Results40
Other pre-specifiedClinic Provider Perspectives on Rapid STI Testing

Clinic provider perspectives will be elicited during a focus group discussion at the conclusion of the clinical study.

Time frame:
at study completion: 12 months

Results for this outcome have not been posted.

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care0/49 (0%)0/49 (0%)0/49 (0%)
Rapid STI Test0/49 (0%)0/49 (0%)0/49 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard of CareRapid STI TestTotal
Median28 (24 to 35)31 (26 to 39)29.5 (25 to 39)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Standard of CareRapid STI TestTotal
Cisgender male342862
Cisgender female131932
Transgender/nonbinary123
Other101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Standard of CareRapid STI TestTotal
Hispanic or Latino10717
Not Hispanic or Latino303565
Unknown or Not Reported9716
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Standard of CareRapid STI TestTotal
American Indian or Alaska Native000
Asian257
Native Hawaiian or Other Pacific Islander000
Black or African American81220
White261844
More than one race134
Unknown or Not Reported121123
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Jarolimova J, Kong D, Sanders G, Shah P, Psaros C, Parker RA, Ard KL, Bassett IV; STI Rapid Testing Research Group (Nancy H Nicholson, CNP 1, Robert P Ober, FNP 1, Vitor G Cardoso, CNP 1, Diane G Kanjilal, CNP 1, Emily L Perriello, CNP 1, Daniel P Worrall, CNP 8). A rapid molecular test for gonorrhea and chlamydia compared to Gram stain for symptomatic patients in a specialized STI clinic: a randomized controlled trial. Sex Transm Dis. 2026 Apr 22:10.1097/OLQ.0000000000002324. doi: 10.1097/OLQ.0000000000002324. Online ahead of print. PubMed 42017665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jun 2024, 15 months.

Results were first posted in Sep 2025, 1 year 2 months after primary completion.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's 15 months is below that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Oct 3, 2022
StartActual
Mar 22, 2023
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024
Results first posted
Sep 23, 2025
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05564299
Collaborators
American Sexually Transmitted Diseases Association
Responsible party
Ingrid V. Bassett, MD, MPH (Associate Professor of Medicine, Massachusetts General Hospital) — Principal investigator
First posted
Oct 3, 2022
Start date
Mar 22, 2023
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Results posted
Sep 23, 2025
Last update
Sep 23, 2025

Study contacts

Ingrid V. Bassett, MD, MPH
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion